AstraZeneca (AZN) → Stock, financial statements
Advertising

AstraZeneca: stocks, financial statements

Dividends News
Favorites

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

  • AZN Ticker
  • 🇺🇸 NYSE, 🇬🇧 LSE Exchange
  • 64,400 Employees
8 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon

Financial statements — AstraZeneca

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
27B 24B 22B 22B 23B
Cost Of Revenue
5.3B 4.9B 4.9B 4.3B 4.1B
Gross Profit
21B 19B 17B 18B 19B
Research and Development
6B 6.1B 5.9B 5.8B 5.9B
Selling General and Admin
12B 12B 10B 11B 9.7B
Operating Expense
23B 23B 21B 21B 20B
Operating Income
3.6B 1.4B 860M 1.8B 3.2B
Other Income Expense Net
150M 150M 96M 130M 410M
EBIT
3.8B 1.4B 840M 1.9B 3.5B
Interest Income
740M 1.3B 760M 680M 680M
Pretax Income
3.9B 1.5B 2B 2.2B 3.6B
Income Tax
770M 320M -57M -640M 150M
Minority Interest
-52M -110M 0 -130M 0
Net Income
3.2B 1.3B 2.1B 3B 3.4B
Net Income Basic
3.2B 1.3B 2.1B 3B 3.4B
20 ← 16 2020 2019 2018 2017 2016
Current cash
8B 6.2B 5.7B 4.6B 5.9B
Short term investments
140M 36M 260M 28M 27M
Receivables
7.4B 6B 5.8B 5.5B 5B
Inventory
4B 3.2B 2.9B 3B 2.3B
Other current assets
140M 36M 260M 28M 27M
Current assets
20B 16B 16B 13B 13B
Long term investments
47B 46B 45B 50B 49B
Property plant equipment
8.3B 7.7B 7.4B 7.6B 6.8B
Goodwill
12B 12B 12B 12B 12B
Intangible assets
21B 21B 22B 26B 28B
Other assets
1.6B 1.4B 670M 1.4B 1.2B
Total assets
67B 61B 61B 63B 63B
Accounts payable
16B 14B 13B 12B 10B
Current long term debt
2.4B 2B 1.8B 2.2B 2.3B
Other current liabilities
2.1B 2.1B 1.7B 2.5B 2.5B
Total current liabilities
20B 18B 16B 16B 15B
Long term debt
18B 16B 17B 16B 15B
Other liabilities
9.9B 10B 9.7B 11B 12B
Minority Interest
16M 1.5B 1.6B 1.7B 1.8B
Total Liabilities
51B 48B 48B 48B 48B
Common stock
2.6B 2.6B 2.5B 2.5B 2.5B
Retained earning
5.3B 2.8B 5.7B 8.2B 8.1B
Treasury stock
0 0 0 0 0
Capital surplus
Shareholder equity
16B 13B 12B 15B 15B
Net tangible assets
-17B -19B -21B -23B -24B
20 ← 16 2020 2019 2018 2017 2016
Net Income
3.2B 1.3B 2.1B 3B 3.4B
Depreciation
3.1B 3.8B 0 0 0
Changes in receivables
1.3B 270M 250M 530M -2B
Changes in inventories
830M 300M -150M 700M 190M
Cash change
1.8B 540M 1.1B -1.3B -950M
Cash flow
4.8B 3B 2.6B 3.6B 4.1B
Capital expenditures
-2.6B -2.5B -1.4B -1.7B -1.4B
Investments
Investing activity other
Total investing cash flows
-290M -660M 960M -2.3B -4B
Dividends paid
Net borrowings
12B 12B 13B 13B 11B
Other financing cash flows
Cash flow financing
-2.2B -1.8B -2B -2.9B -1.3B
Exchange rate effect